Safety and Efficacy of Simplified EMR Versus ESD for Rectal Neuroendocrine Tumors ≤ 10 Mm: A Retrospective Cohort Study
Abstract
1. Introduction
2. Method
2.1. Study Design
2.2. Patient Population
2.3. Interventions
2.3.1. Procedure of sEMR
2.3.2. Procedure of ESD
2.4. Pathological Evaluation
2.5. Data Collection
2.6. Outcome Measures
2.7. Statistical Analysis
3. Result
3.1. Baseline Characteristics
3.2. Operation Time and Material Cost
3.3. Histopathological Findings
3.4. Margin Status Analysis
3.5. Multivariate Analysis of Margin Status
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Xu, Z.; Wang, L.; Dai, S.; Chen, M.; Li, F.; Sun, J.; Luo, F. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Netw. Open 2021, 4, e2124750. [Google Scholar] [CrossRef]
- Scherübl, H. Rectal carcinoids are on the rise: Early detection by screening endoscopy. Endoscopy 2009, 41, 162–165. [Google Scholar] [CrossRef]
- Basuroy, R.; Haji, A.; Ramage, J.K.; Quaglia, A.; Srirajaskanthan, R. Review article: The investigation and management of rectal neuroendocrine tumours. Aliment. Pharmacol. Ther. 2016, 44, 332–345. [Google Scholar] [CrossRef]
- Fahy, B.N.; Tang, L.H.; Klimstra, D.; Wong, W.D.; Guillem, J.G.; Paty, P.B.; Temple, L.K.; Shia, J.; Weiser, M.R. Carcinoid of the rectum risk stratification (CaRRS): A strategy for preoperative outcome assessment. Ann. Surg. Oncol. 2007, 14, 396–404. [Google Scholar] [CrossRef] [PubMed]
- Ngamruengphong, S.; Kamal, A.; Akshintala, V.; Hajiyeva, G.; Hanada, Y.; Chen, Y.I.; Sanaei, O.; Fluxa, D.; Haito Chavez, Y.; Kumbhari, V.; et al. Prevalence of metastasis and survival of 788 patients with T1 rectal carcinoid tumors. Gastrointest. Endosc. 2019, 89, 602–606. [Google Scholar] [CrossRef]
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors; Version 2.2025. 2025. Available online: https://www.nccn.org/guidelines/guidelines-detail?id=1448 (accessed on 15 July 2025).
- Zhuang, X.; Zhang, S.; Chen, G.; Luo, Z.; Hu, H.; Huang, W.; Guo, Y.; Ouyang, Y.; Peng, L.; Qing, Q.; et al. Risk factors and clinical outcomes of incomplete endoscopic resection of small rectal neuroendocrine tumors in southern China: A 9-year data analysis. Gastroenterol. Rep. 2023, 11, goac084. [Google Scholar] [CrossRef] [PubMed]
- Fine, C.; Roquin, G.; Terrebonne, E.; Lecomte, T.; Coriat, R.; Do Cao, C.; de Mestier, L.; Coffin, E.; Cadiot, G.; Nicolli, P.; et al. Endoscopic management of 345 small rectal neuroendocrine tumours: A national study from the French group of endocrine tumours (GTE). United Eur. Gastroenterol. J. 2019, 7, 1102–1112. [Google Scholar] [CrossRef] [PubMed]
- Matsuno, K.; Miyamoto, H.; Kitada, H.; Yoshimatsu, S.; Tamura, F.; Sakurai, K.; Fukubayashi, K.; Shono, T.; Setoyama, H.; Matsuyama, T.; et al. Comparison of endoscopic submucosal resection with ligation and endoscopic submucosal dissection for small rectal neuroendocrine tumors: A multicenter retrospective study. DEN Open 2023, 3, e163. [Google Scholar] [CrossRef]
- Cha, B.; Shin, J.; Ko, W.J.; Kwon, K.S.; Kim, H. Prognosis of incompletely resected small rectal neuroendocrine tumor using endoscope without additional treatment. BMC Gastroenterol. 2022, 22, 293. [Google Scholar] [CrossRef]
- Ono, A.; Fujii, T.; Saito, Y.; Matsuda, T.; Lee, D.T.; Gotoda, T.; Saito, D. Endoscopic submucosal resection of rectal carcinoid tumors with a ligation device. Gastrointest. Endosc. 2003, 57, 583–587. [Google Scholar] [CrossRef]
- Kim, H.H.; Park, S.J.; Lee, S.H.; Park, H.U.; Song, C.S.; Park, M.I.; Moon, W. Efficacy of endoscopic submucosal resection with a ligation device for removing small rectal carcinoid tumor compared with endoscopic mucosal resection: Analysis of 100 cases. Dig. Endosc. 2012, 24, 159–163. [Google Scholar] [CrossRef]
- Park, S.B.; Kim, H.W.; Kang, D.H.; Choi, C.W.; Kim, S.J.; Nam, H.S. Advantage of endoscopic mucosal resection with a cap for rectal neuroendocrine tumors. World J. Gastroenterol. 2015, 21, 9387–9393. [Google Scholar] [CrossRef]
- So, H.; Yoo, S.H.; Han, S.; Kim, G.U.; Seo, M.; Hwang, S.W.; Yang, D.H.; Byeon, J.S. Efficacy of Precut Endoscopic Mucosal Resection for Treatment of Rectal Neuroendocrine Tumors. Clin. Endosc. 2017, 50, 585–591. [Google Scholar] [CrossRef] [PubMed]
- Li, D.; Xie, J.; Hong, D.; Liu, G.; Wang, R.; Jiang, C.; Ye, Z.; Xu, B.; Wang, W. Efficacy and safety of ligation-assisted endoscopic submucosal resection combined with endoscopic ultrasonography for treatment of rectal neuroendocrine tumors. Scand. J. Gastroenterol. 2022, 57, 734–739. [Google Scholar] [CrossRef]
- Kim, J.; Kim, J.; Oh, E.H.; Ham, N.S.; Hwang, S.W.; Park, S.H.; Ye, B.D.; Byeon, J.-S.; Myung, S.-J.; Yang, S.-K. Anchoring the snare tip is a feasible endoscopic mucosal resection method for small rectal neuroendocrine tumors. Sci. Rep. 2021, 11, 12918. [Google Scholar] [CrossRef] [PubMed]
- Chen, T.; Yao, L.Q.; Xu, M.D.; Zhang, Y.Q.; Chen, W.F.; Shi, Q.; Cai, S.L.; Chen, Y.Y.; Xie, Y.H.; Ji, Y.; et al. Efficacy and Safety of Endoscopic Submucosal Dissection for Colorectal Carcinoids. Clin. Gastroenterol. Hepatol. 2016, 14, 575–581. [Google Scholar] [CrossRef]
- Onozato, Y.; Kakizaki, S.; Iizuka, H.; Sohara, N.; Mori, M.; Itoh, H. Endoscopic treatment of rectal carcinoid tumors. Dis. Colon. Rectum 2010, 53, 169–176. [Google Scholar] [CrossRef] [PubMed]
- Son, H.J.; Sohn, D.K.; Hong, C.W.; Han, K.S.; Kim, B.C.; Park, J.W.; Choi, H.S.; Chang, H.J.; Oh, J.H. Factors associated with complete local excision of small rectal carcinoid tumor. Int. J. Color. Dis. 2013, 28, 57–61. [Google Scholar] [CrossRef]
- Gao, X.; Huang, S.; Wang, Y.; Peng, Q.; Li, W.; Zou, Y.; Han, Z.; Cai, J.; Luo, Y.; Ye, Y.; et al. Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors </=10 mm: A Randomized Noninferiority Trial. Am. J. Gastroenterol. 2022, 117, 1982–1989. [Google Scholar] [CrossRef] [PubMed]
- Ueda, T.; Yoshii, S.; Kanesaka, T.; Tani, Y.; Ando, Y.; Tanabe, G.; Fujimoto, Y.; Ito, N.; Tsukuda, N.; Matsuyama, K.; et al. Endoscopic Submucosal Resection Using a Ligation Band without Injection for Rectal Neuroendocrine Tumors. Gastrointest. Endosc. 2025. [Google Scholar] [CrossRef]
- Nagtegaal, I.D.; Odze, R.D.; Klimstra, D.; Paradis, V.; Rugge, M.; Schirmacher, P.; Washington, K.M.; Carneiro, F.; Cree, I.A. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020, 76, 182–188. [Google Scholar] [CrossRef] [PubMed]
- Kulke, M.H.; Mayer, R.J. Carcinoid tumors. N. Engl. J. Med. 1999, 340, 858–868. [Google Scholar] [CrossRef] [PubMed]
- Bertani, E.; Ravizza, D.; Milione, M.; Massironi, S.; Grana, C.M.; Zerini, D.; Piccioli, A.N.; Spinoglio, G.; Fazio, N. Neuroendocrine neoplasms of rectum: A management update. Cancer Treat. Rev. 2018, 66, 45–55. [Google Scholar] [CrossRef] [PubMed]
- Kang, H.S.; Kwon, M.J.; Kim, T.H.; Han, J.; Ju, Y.S. Lymphovascular invasion as a prognostic value in small rectal neuroendocrine tumor treated by local excision: A systematic review and meta-analysis. Pathol. Res. Pract. 2019, 215, 152642. [Google Scholar] [CrossRef]
- Kim, J.; Kim, J.Y.; Oh, E.H.; Yoo, C.; Park, I.J.; Yang, D.H.; Ryoo, B.Y.; Ryu, J.S.; Hong, S.M. Chromogranin A Expression in Rectal Neuroendocrine Tumors Is Associated With More Aggressive Clinical Behavior and a Poorer Prognosis. Am. J. Surg. Pathol. 2020, 44, 1496–1505. [Google Scholar] [CrossRef]
sEMR Group (n = 37) | ESD Group (n = 37) | p Value | |
---|---|---|---|
Age | 49.4 ± 11.0 | 48.6 ± 10.3 | 0.752 |
Male/Female | 16/21 | 16/21 | 1.000 |
Clinical symptoms | 0.878 | ||
Incidental finding | 25 (67.6%) | 28 (75.7%) | |
Abdominal pain/distention | 6 (16.2%) | 4 (10.8%) | |
Change in bowel habits | 5 (13.5%) | 4 (10.8%) | |
Others | 1 (2.7%) | 1 (2.7%) | |
Distance from anal verge (cm) | 5 (5–8) | 5 (4–8) | 0.611 |
Tumor size (mm) | 5 (5–7) | 6 (4–8) | 0.804 |
Endoscopy ultrasound before operation | 31 (83.8%) | 28 (75.7%) | 0.563 |
En bloc resection | 37 (100%) | 37 (100%) | 1.000 |
Intraoperative bleeding | 1 (2.7%) | 8 (21.6%) | 0.028 * |
Perforation | 0 | 0 | 1.000 |
Operation time (second) | 409 (324–648) | 1469 (1106–1803) | <0.001 |
Material cost (CNY) | 1486 (1341–1565) | 6390 (5159–7713) | <0.001 |
sEMR Group (n = 37) | ESD Group (n = 37) | p Value | |
---|---|---|---|
Tumor grade | 0.560 | ||
G1 | 31 | 32 | |
G2 | 3 | 4 | |
Indeterminate | 3 | 1 | |
Resection margin | 0.019 * | ||
R0 resection | 34 | 25 | |
R1 resection | 3 | 12 | |
Lymphovascular invasion | 1 (2.7%) | 2 (5.4%) | 1.000 |
Immunohistochemistry for Chromogranin A | 22/34 (64.7%) | 24/36 (66.7%) | 1.000 |
Immunohistochemistry for Synaptophysin | 35/35 (100%) | 35/36 (97.2%) | 1.000 |
R1 Resection Group (n = 15) | R0 Resection Group (n = 59) | p Value | |
---|---|---|---|
Age | 49.0 ± 9.7 | 49.0 ± 10.9 | 0.996 |
Male/Female | 6/9 | 26/33 | 1.000 |
Clinical symptoms | 0.514 | ||
Incidental finding | 12 (80.0%) | 41 (69.5%) | |
Abdominal pain/distention | 1 (6.7%) | 9 (15.3%) | |
Change in bowel habits | 1 (6.7%) | 8 (13.6%) | |
Others | 1 (6.7%) | 1 (1.7%) | |
Distance from anal verge (cm) | 7 (5–10) | 5 (5–8) | 0.229 |
Tumor size (mm) | 6 (5–7.5) | 5 (4–7.5) | 0.362 |
Endoscopy ultrasound before operation | 10 (66.7%) | 49 (83.1%) | 0.294 |
En bloc resection | 15 (100%) | 59 (100%) | 1.000 |
Intraoperative bleeding | 3 (20.0%) | 6 (10.2%) | 0.550 |
Perforation | 0 | 0 | 1.000 |
Tumor grade | 0.571 | ||
G1 | 14 (93.3%) | 49 (83.1%) | |
G2 | 1 (6.7%) | 6 (10.2%) | |
Indeterminate | 0 | 4 (6.8%) | |
Lymphovascular invasion | 3 (20.0%) | 0 | 0.006 * |
Immunohistochemistry for Chromogranin A | 13/15 (86.7%) | 33/56 (58.9%) | 0.105 |
Immunohistochemistry for Synaptophysin | 14/15 (93.3%) | 56/56 (100%) | 0.476 |
Variable | Odds Ratio (OR) | 95% Confidence Interval | p Value |
---|---|---|---|
Procedure (sEMR vs. ESD) | 0.19 | 0.03–0.72 | 0.013 * |
Lymphovascular invasion | 28.7 | 1.94–445 | 0.012 * |
Immunohistochemistry | 3.03 | 0.74–17.54 | 0.130 |
for Chromogranin A |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zou, L.; Zou, L.; Yang, Y.; Zhou, W.; Wu, X.; Guo, T.; Jiang, Q.; Feng, Y.; Zhang, S.; Wang, Q.; et al. Safety and Efficacy of Simplified EMR Versus ESD for Rectal Neuroendocrine Tumors ≤ 10 Mm: A Retrospective Cohort Study. J. Clin. Med. 2025, 14, 6125. https://doi.org/10.3390/jcm14176125
Zou L, Zou L, Yang Y, Zhou W, Wu X, Guo T, Jiang Q, Feng Y, Zhang S, Wang Q, et al. Safety and Efficacy of Simplified EMR Versus ESD for Rectal Neuroendocrine Tumors ≤ 10 Mm: A Retrospective Cohort Study. Journal of Clinical Medicine. 2025; 14(17):6125. https://doi.org/10.3390/jcm14176125
Chicago/Turabian StyleZou, Linfeng, Long Zou, Yingyun Yang, Weixun Zhou, Xi Wu, Tao Guo, Qingwei Jiang, Yunlu Feng, Shengyu Zhang, Qiang Wang, and et al. 2025. "Safety and Efficacy of Simplified EMR Versus ESD for Rectal Neuroendocrine Tumors ≤ 10 Mm: A Retrospective Cohort Study" Journal of Clinical Medicine 14, no. 17: 6125. https://doi.org/10.3390/jcm14176125
APA StyleZou, L., Zou, L., Yang, Y., Zhou, W., Wu, X., Guo, T., Jiang, Q., Feng, Y., Zhang, S., Wang, Q., & Yang, A. (2025). Safety and Efficacy of Simplified EMR Versus ESD for Rectal Neuroendocrine Tumors ≤ 10 Mm: A Retrospective Cohort Study. Journal of Clinical Medicine, 14(17), 6125. https://doi.org/10.3390/jcm14176125